SciELO - Scientific Electronic Library Online

 
vol.114 issue6Blood lead levels in children aged between 1 and 6 years old in La Plata, Argentina: Identification of risk factors for lead exposurePrevalence and clinical course of typical hemolytic uremic syndrome among siblings author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Archivos argentinos de pediatría

Print version ISSN 0325-0075On-line version ISSN 1668-3501

Abstract

ONORATELI, Myriam et al. Humoral immunity to tetanus, measles and rubella in children with acute lymphoblastic leukemia after chemotherapy. Arch. argent. pediatr. [online]. 2016, vol.114, n.6, pp.549-552. ISSN 0325-0075.  http://dx.doi.org/10.5546/aap.2016.549.

Chemotherapy regimens and clinical support advances have improved survival in children with acute lymphoblastic leukemia. The after-effects of treatment are a reason for concern, including damage to the immune system induced by immunosuppressive therapy which is reflected in the loss of antibody protection provided by prior immunizations. Our goal was to assess the presence of measles, rubella, and tetanus protective antibody titers among patients with acute lymphoblastic leukemia after completing chemotherapy. Sixty-one children with acute lymphoblastic leukemia seen at the Hospital Garrahan were included; patients had finished their chemotherapy at least 6 months earlier and had a complete immunization schedule before diagnosis. The rates of protective antibodies were 46% (CI: 32-59) for measles, 53% (CI 40-67) for tetanus, and 60% (CI 47-63) for rubella. These results strengthen the need to reconsider revaccination in this group of patients.

Keywords : Acute lymphoblastic leukemia; Immunizations; Humoral immunity; Antibodies; Chemotherapy.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf ) | Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License